Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis.

CONCLUSION: Continuous apremilast treatment resulted in sustained improvements in PsA for up to 52 weeks. Apremilast had an acceptable safety profile and was generally well tolerated. Clinical trial registration: NCT01172938. PMID: 25593233 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25593233?dopt=Abstract

Source: J Rheumatol - January 15, 2015 Category: Rheumatology Authors: Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S Tags: J Rheumatol Source Type: research